Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | CCR1 | P32246 | 2/20 | 0.64 |
| ▸ | CCR5 | P51681 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3149939 | 0.96 | ABCB11 (0.60) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| SCHEMBL3154883 | 0.93 | ABCB11 (0.65) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| SCHEMBL3150098 | 0.91 | ABCB11 (0.63) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| SCHEMBL3135724 | 0.91 | ABCB11 (0.72) | ABCB11CCR1CCR5MCHR1SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL3150509 | 0.89 | ABCB11 (0.60) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| Trifluoroacetic Acid SCHEMBL3149814 | 0.88 | ABCB11 (0.59) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| SCHEMBL3140426 | 0.88 | ABCB11 (0.63) | ABCB11CCR1CCR5SIGMAR1BCHE | |
| Trifluoroacetic Acid SCHEMBL3149755 | 0.87 | ABCB11 (0.67) | ABCB11CCR1MCHR1SIGMAR1BCHE | |
| SCHEMBL3149960 | 0.87 | ABCB11 (0.62) | ABCB11CCR1CCR5MCHR1PTGDR2 | |
| SCHEMBL3143942 | 0.87 | ABCB11 (0.59) | ABCB11CCR1SIGMAR1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | ABCB11 477/4885CCR1 1/4885CCR5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.